<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13632">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00382408</url>
  </required_header>
  <id_info>
    <org_study_id>DR-ADV-301</org_study_id>
    <nct_id>NCT00382408</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duramed Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the
      safety and efficacy of oral DR-5001 in reducing the attack rate of febrile acute respiratory
      disease caused by type-4 and type-7 adenovirus as well as determine its immunogenicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted at two sites and will include a minimum of 4 visits. The overall
      study duration for participants will be approximately 8 weeks. Study participants will
      undergo acute respiratory disease evaluation that will include a throat swab and a blood
      draw. Each participant will also be contacted in six months for follow-up information.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Participants With Throat Culture Positive for Wild Type-4 Adenovirus (ADV) Infection</measure>
    <time_frame>At Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>For the oral Type-4 vaccine, the attack rate of the febrile Type-4 ADV-associated ARD cases observed among subjects in the vaccine group and placebo group from the day of study medication administration (Day 0) to the final study visit (Day 56) will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Throat Culture Positive for Wild Type-7 Adenovirus (ADV) Infection</measure>
    <time_frame>At Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>For the oral Type-7 vaccine, seroconversion rates observed at Week 4 (Day 26) for the oral Type-7 ADV vaccine and placebo groups will be calculated. For the purpose of inference, evaluation of reduction in ADV-4 febrile ARD attack rate will be tested first. If the criterion for success is met, then evaluation of ADV-7 seroconversion will proceed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of ADV Type-4 Booster Participants With Increase in Titer</measure>
    <time_frame>Baseline to end of Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>ADV-4 booster effect: is defined as the development of ADV Type-4 neutralizing antibody at Week 4 (Day 26) that represents at least a fourfold increase in titer from baseline (Visit 0) in a subject whose baseline Type-4 titer is ≥1:4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ADV Type-7 Booster Participants With Increase in Titer</measure>
    <time_frame>Baseline to end of Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>ADV-7 booster effect: is defined as the development of ADV Type-7 neutralizing antibody at Week 4 (Day 26) that represents at least a fourfold increase in titer from baseline (Visit 0) in a subject whose baseline Type-7 titer is ≥1:4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4041</enrollment>
  <condition>Respiratory Tract Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DR-5001</intervention_name>
    <description>1 tablet x 1</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet x 1</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Military recruit in training

          -  Male or female; if female, must be of non-childbearing potential or with a documented
             negative pregnancy test &lt;/= 72 hours prior to study medication administration and
             agree not to become pregnant

        Exclusion Criteria:

          -  Female nursing an infant or planning on nursing during the study

          -  Immunosuppressed for any reason, including past (within last 6 months) or current
             treatment with immunosuppressive therapy

          -  Known allergy to any component of the vaccines and/or placebo tablets

          -  Immunocompromised sexual partner or immunocompromised individuals in home
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duramed Protocol Chair</last_name>
    <role>Study Chair</role>
    <affiliation>Duramed Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Great Lakes</city>
        <state>Illinois</state>
        <zip>60088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Fort Jackson</city>
        <state>South Carolina</state>
        <zip>29207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 24, 2012</lastchanged_date>
  <firstreceived_date>September 27, 2006</firstreceived_date>
  <firstreceived_results_date>July 28, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute respiratory disease prevention</keyword>
  <keyword>Adenovirus</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vaccine</title>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3031"/>
                <participants group_id="P2" count="1009"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2887"/>
                <participants group_id="P2" count="955"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet protocol requirement</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vaccine</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3031"/>
                <measurement group_id="B2" value="1009"/>
                <measurement group_id="B3" value="4040"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="21.3" spread="4.0"/>
                <measurement group_id="B2" value="21.1" spread="4.1"/>
                <measurement group_id="B3" value="21.2" spread="4.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Between 17 and 43 years</description>
          <units>Years</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3031"/>
                <measurement group_id="B2" value="1009"/>
                <measurement group_id="B3" value="4040"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1121"/>
                <measurement group_id="B2" value="367"/>
                <measurement group_id="B3" value="1488"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1910"/>
                <measurement group_id="B2" value="642"/>
                <measurement group_id="B3" value="2552"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3031"/>
                <measurement group_id="B2" value="1009"/>
                <measurement group_id="B3" value="4040"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Throat Culture Positive for Wild Type-4 Adenovirus (ADV) Infection</title>
        <description>For the oral Type-4 vaccine, the attack rate of the febrile Type-4 ADV-associated ARD cases observed among subjects in the vaccine group and placebo group from the day of study medication administration (Day 0) to the final study visit (Day 56) will be calculated.</description>
        <time_frame>At Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subjects undergoing military basic training and randomly assigned to the intent-to-treat (ITT) cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Oral Type-4 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral Type-4 Placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1739"/>
                  <measurement group_id="O2" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Throat Culture Positive for Wild Type-4 Adenovirus (ADV) Infection</title>
            <description>For the oral Type-4 vaccine, the attack rate of the febrile Type-4 ADV-associated ARD cases observed among subjects in the vaccine group and placebo group from the day of study medication administration (Day 0) to the final study visit (Day 56) will be calculated.</description>
            <units>participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="94.5" lower_limit="93.4" upper_limit="95.5"/>
                  <measurement group_id="O2" value="10.6" lower_limit="8.2" upper_limit="12.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Throat Culture Positive for Wild Type-7 Adenovirus (ADV) Infection</title>
        <description>For the oral Type-7 vaccine, seroconversion rates observed at Week 4 (Day 26) for the oral Type-7 ADV vaccine and placebo groups will be calculated. For the purpose of inference, evaluation of reduction in ADV-4 febrile ARD attack rate will be tested first. If the criterion for success is met, then evaluation of ADV-7 seroconversion will proceed.</description>
        <time_frame>At Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subjects undergoing military basic training and randomly assigned to the intent-to-treat (ITT) cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Oral Type-7 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral Type-7 placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1051"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Throat Culture Positive for Wild Type-7 Adenovirus (ADV) Infection</title>
            <description>For the oral Type-7 vaccine, seroconversion rates observed at Week 4 (Day 26) for the oral Type-7 ADV vaccine and placebo groups will be calculated. For the purpose of inference, evaluation of reduction in ADV-4 febrile ARD attack rate will be tested first. If the criterion for success is met, then evaluation of ADV-7 seroconversion will proceed.</description>
            <units>participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="93.8" lower_limit="92.4" upper_limit="95.2"/>
                  <measurement group_id="O2" value="5.3" lower_limit="3.0" upper_limit="7.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of ADV Type-4 Booster Participants With Increase in Titer</title>
        <description>ADV-4 booster effect: is defined as the development of ADV Type-4 neutralizing antibody at Week 4 (Day 26) that represents at least a fourfold increase in titer from baseline (Visit 0) in a subject whose baseline Type-4 titer is ≥1:4.</description>
        <time_frame>Baseline to end of Week 8</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subjects undergoing military basic training and randomly assigned to the intent-to-treat (ITT) booster cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>ADV Type-4 Booster</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>ADV Type-4-booster placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="550"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of ADV Type-4 Booster Participants With Increase in Titer</title>
            <description>ADV-4 booster effect: is defined as the development of ADV Type-4 neutralizing antibody at Week 4 (Day 26) that represents at least a fourfold increase in titer from baseline (Visit 0) in a subject whose baseline Type-4 titer is ≥1:4.</description>
            <units>participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50.3" lower_limit="47.3" upper_limit="53.2"/>
                  <measurement group_id="O2" value="0.6" lower_limit="-0.2" upper_limit="1.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of ADV Type-7 Booster Participants With Increase in Titer</title>
        <description>ADV-7 booster effect: is defined as the development of ADV Type-7 neutralizing antibody at Week 4 (Day 26) that represents at least a fourfold increase in titer from baseline (Visit 0) in a subject whose baseline Type-7 titer is ≥1:4.</description>
        <time_frame>Baseline to end of Week 8</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subjects undergoing military basic training and randomly assigned to the intent-to-treat (ITT) booster cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Oral Type-7 booster vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral Type-7-booster placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="836"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of ADV Type-7 Booster Participants With Increase in Titer</title>
            <description>ADV-7 booster effect: is defined as the development of ADV Type-7 neutralizing antibody at Week 4 (Day 26) that represents at least a fourfold increase in titer from baseline (Visit 0) in a subject whose baseline Type-7 titer is ≥1:4.</description>
            <units>participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46.1" lower_limit="43.8" upper_limit="48.4"/>
                  <measurement group_id="O2" value="3.9" lower_limit="2.4" upper_limit="5.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The reporting period for adverse events was from the time the informed consent was signed until study visit 4 (week 8) or early termination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vaccine</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Graves Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Hemotochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Acute Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pain due to Acute Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Acute Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Drug Overdose</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Acute Electrical Injury Secondary to Lightening Strike</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Broken Jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Fractured Spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Knee ACL Injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Allergic reaction to Peanuts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Head Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Auto Accident</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Arm Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Leg Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment Disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Depressive Disorder and Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Cyclothymic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Personality Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Suicide Thoughts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Bipolar Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Mixed Episode with Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile ARD Associated with Vaccine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2786" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="947" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="552" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="193" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="482" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="387" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1193" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="424" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="475" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="788" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="270" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="233" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1237" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="447" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="743" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="233" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="740" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="685" subjects_at_risk="3031"/>
                <counts group_id="E2" subjects_affected="238" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can (i) review results communications prior to public release and can embargo communications regarding trial results for a period of at least 60 days but no more than 180 days from the time submitted to the sponsor for review; and (ii) require in instances of a multi-center study, that a single PI not disclose study data until after the multi-center results are published, provided such results are published within eighteen (18) months of the conclusion of the study.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In the past 6 years, Type-7 ADV has only rarely been recovered from recruits with ARD (Russell 2007). Therefore, it may not be possible to directly measure the protective effect of the vaccine against Type-7 ADV in the proposed study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Duramed Research Protocol Chair</name_or_title>
      <organization>Duramed Research</organization>
      <phone>215-293-7279</phone>
      <email>medicalaffairs@barrlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
